Page 26 - Read Online

Page 14 of 14 Daniele et al. Hepatoma Res 2021;7:61 https://dx.doi.org/10.20517/2394-5079.2021.58

8. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med 2008;359:378-90. DOI PubMed
9. Cheng A, Kang Y, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular
carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34. DOI PubMed
10. Granito A, Bolondi L. Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis.
Lancet Oncol 2017;18:e101-12. DOI PubMed
11. Bruix J, Sherman M; Practice Guidelines Committee; American Association for the Study of Liver Diseases. Management of
hepatocellular carcinoma. Hepatology 2005;42:1208-36. DOI
12. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-
of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76. DOI PubMed
13. Blazeby JM, Currie E, Zee BC, Chie WC, Poon RT, Garden OJ; EORTC Quality of Life Group. Development of a questionnaire
module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-
HCC18. Eur J Cancer 2004;40:2439-44. DOI PubMed
14. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version
1.1). Eur J Cancer 2009;45:228-47. DOI PubMed
15. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343-6. DOI PubMed
16. Perrone F, Gallo C, Daniele B, et al; Cancer of Liver Italian Program (CLIP) Investigators. Tamoxifen in the treatment of
hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial. Curr Pharm Des 2002;8:1013-9. DOI
PubMed
17. Pinter M, Sieghart W, Graziadei I, et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver
cirrhosis. Oncologist 2009;14:70-6. DOI PubMed
18. Abou-Alfa GK, Amadori D, Santoro A, et al. Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and
Child-Pugh A versus B cirrhosis. Gastrointest Cancer Res 2011;4:40-4. PubMed PMC
19. Kim JE, Ryoo BY, Ryu MH, et al. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer
Chemother Pharmacol 2011;68:1285-90. DOI PubMed
20. Pressiani T, Boni C, Rimassa L, et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a
prospective feasibility analysis. Ann Oncol 2013;24:406-11. DOI PubMed
21. Marrero JA, Kudo M, Venook AP, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the
GIDEON study. J Hepatol 2016;65:1140-7. DOI PubMed
22. Ganten TM, Stauber RE, Schott E, et al. Sorafenib in patients with hepatocellular carcinoma-results of the observational INSIGHT
study. Clin Cancer Res 2017;23:5720-8. DOI PubMed
23. McNamara MG, Slagter AE, Nuttall C, et al. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular
carcinoma-a meta-analysis. Eur J Cancer 2018;105:1-9. DOI PubMed
24. Blanc JF, Khemissa F, Bronowicki JP, et al; PRODIGE 21 collaborators. Phase 2 trial comparing sorafenib, pravastatin, their
combination or supportive care in HCC with Child-Pugh B cirrhosis. Hepatol Int 2021;15:93-104. DOI PubMed
25. Vogel A, Frenette C, Sung MW, et al. Baseline liver function and outcomes in the phase III REFLECT study in patients with
unresectable hepatocellular carcinoma (uHCC). J Clin Oncol 2020;38:524. DOI
26. Chan S, Miksad R, Cicin I, et al. Outcomes based on albumin-bilirubin (ALBI) grade in the phase III CELESTIAL trial of
cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC). Ann Oncol 2019;30:ix45-6. DOI
27. Kudo M, Galle PR, Brandi G, et al. Effect of ramucirumab on ALBI grade in patients with advanced HCC: results from REACH and
REACH-2. JHEP Rep 2021;3:100215. DOI PubMed PMC
28. Labeur TA, Achterbergh R, Takkenberg B, Van Delden O, Mathôt R, Klümpen HJ. Sorafenib for patients with hepatocellular
carcinoma and Child-Pugh B liver cirrhosis: lessons learned from a terminated study. Oncologist 2020;25:e1274-9. DOI PubMed
PMC
29. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment
(RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66. DOI PubMed
30. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular
carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73. DOI PubMed
31. Kudo M, Matilla A, Santoro A, et al. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced
hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol 2021;S0168-8278(21)00313. DOI PubMed
32. El-Khoueiry AB, Hanna DL, Llovet J, Kelley RK. Cabozantinib: an evolving therapy for hepatocellular carcinoma. Cancer Treat Rev
2021;98:102221. DOI PubMed
33. Daniele G, Costa N, Lorusso V, Costa-Maia J, Pache I, Pirisi M. Methodological assessment of HCC literature. Ann Oncol 2013;24
Suppl 2:ii6-14. DOI PubMed PMC